Quality by Design Methodology Applied to Process Optimization and Scale up of Curcumin Nanoemulsions Produced by Catastrophic Phase Inversion
DOI
10.3390/pharmaceutics13060880
Document Type
Journal Article
Publication Date
6-15-2021
Publication Title
Pharmaceutics
Volume
13
Issue
6
ISSN
1999-4923
Keywords
catastrophic phase inversion, multiple linear regression, nanoemulsion, quality by design
Abstract
In the presented study, we report development of a stable, scalable, and high-quality curcumin-loaded oil/water (o / w) nanoemulsion manufactured by concentration-mediated catastrophic phase inversion as a low energy nanoemulsification strategy. A design of experiments (DoE) was constructed to determine the effects of process parameters on the mechanical input required to facilitate the transition from the gel phase to the final o/w nanoemulsion and the long-term effects of the process parameters on product quality. A multiple linear regression (MLR) model was constructed to predict nanoemulsion diameter as a function of nanoemulsion processing parameters. The DoE and subsequent MLR model results showed that the manufacturing process with the lowest temperature (25 °C), highest titration rate (9 g/ minute), and lowest stir rate (100 rpm) produced the highest quality nanoemulsion. Both scales of CUR-loaded nanoemulsions (100 g and 500 g) were comparable to the drug-free optimal formulation with 148.7 nm and 155.1 nm diameter, 0.22 and 0.25 PDI, and 96.29 ± 0.76% and 95.60 ± 0.88% drug loading for the 100 g and 500 g scales, respectively. Photostability assessments indicated modest loss of drug ( < 10%) upon UV exposure of 24 h, which is appropriate for intended transdermal applications, with expected reapplication of every 6-8 h.
Open Access
OA
Preprint
Repository Citation
Adena, S. K., Herneisey, M., Pierce, E., Hartmeier, P. R., Adlakha, S., Hosfeld, M. A., Drennen, J. K., & Janjic, J. M. (2021). Quality by Design Methodology Applied to Process Optimization and Scale up of Curcumin Nanoemulsions Produced by Catastrophic Phase Inversion. Pharmaceutics, 13 (6). https://doi.org/10.3390/pharmaceutics13060880